新诺威：关于本次交易相关主体不存在依据《上市公司监管指引第7号——上市公司重大资产重组相关股票异常交易监管》第十二条及《深圳证券交易所上市公司自律监管指引第8号——重大资产重组（2023年修订）》第三十条规定的不得参与上市公司重大资产重组情形的说明

CSPC Innovation Pharmaceutical: Regarding this trade, the relevant parties do not meet the requirements outlined in Article 12 of the "Guidelines for the Supervision of Listed Companies No. 7 - Supervision of Unusual Stock Trades Related to Major Asset Restructuring of Listed Companies" and Article 30 of the "Self-Regulatory Guidelines for Listed Companies in Shenzhen Stock Exchange No. 8 - Major Asset Restructuring (Revised in 2023)" and may not participate in the major asset restructuring of listed companies.